EXPLORER-HCM: CAMZYOS (mavacamten) demonstrated significant improvements across all analysed secondary endpoints vs placebo at Week 301,2
Secondary endpoint
CAMZYOS significantly improved post-exercise LVOT obstruction vs placebo at Week 301,2
Change in mean post-exercise LVOT peak gradient from baseline to Week 301,2
Adapted from Olivotto I et al. 2020.2
*96% of patients in the CAMZYOS treatment arm received background therapy with beta blocker or calcium channel blocker (76% [94/123] and 20% [25/123], respectively) vs 87% in the placebo arm (74% [95/128] and 13% [17/128], respectively).1,2
relative improvement in post-exercise LVOT
obstruction vs placebo at Week 301,2
Secondary endpoint
CAMZYOS significantly improved peak oxygen consumption (pVO2) vs placebo at Week 301,2
Mean change in pVO2 from baseline to Week 301,2
Treatment difference, 1.4; 95% CI: 0.6 to 2; p<0.0006
Adapted from Olivotto I et al. 2020.2
*96% of patients in the CAMZYOS treatment arm received background therapy with beta blocker or calcium channel blocker (76% [94/123] and 20% [25/123], respectively) vs 87% in the placebo arm (74% [95/128] and 13% [17/128], respectively).1,2
Secondary endpoint
Significantly more patients improved by ≥1 NYHA class with CAMZYOS vs placebo at Week 301,2
Percentage of patients who improved NYHA score by ≥1 class from baseline to Week 301,2
Treatment difference, 34%; 95% CI: 22 to 45; p<0.0001
Adapted from Olivotto I et al. 2020.2
*96% of patients in the CAMZYOS treatment arm received background therapy with beta blocker or calcium channel blocker (76% [94/123] and 20% [25/123], respectively) vs 87% in the placebo arm (74% [95/128] and 13% [17/128], respectively).1,2
as many patients improved by ≥1 NYHA
class vs placebo at Week 301,2
Secondary endpoint
CAMZYOS demonstrated significant improvements in patient-reported symptom burden and physical limitations vs placebo1,2
The KCCQ-23 CSS is derived from the Total Symptoms Score (TSS) and the Physical Limitations (PL) score of the KCCQ-23. The CSS ranges from 0 to 100, with higher scores representing better health status1
KCCQ-23 CSS: mean change from baseline to Week 30*1,3
Adapted from Spertus JA et al. 2021.3
*Due to the smaller numbers evaluable for patient-reported outcome endpoints, additional post hoc analyses compared the reasons for missing data.2
CAMZYOS demonstrated significant improvements vs placebo in
patient-reported symptom burden and physical limitations as early as Week 6, with this improvement remaining consistent up to Week 301
Secondary endpoint
CAMZYOS demonstrated significant mean improvements in patient-reported frequency and severity of shortness of breath vs placebo1,2
The HCMSQ-SoB domain score measures frequency and severity of shortness of breath. The HCMSQ-SoB domain score ranges from 0 to 18, with lower scores representing less shortness of breath1
HCMSQ-SoB domain score: mean change from baseline to Week 30*1,4
Adapted from Naidu SS et al. 2021.4
*Due to the smaller numbers evaluable for patient-reported outcome endpoints, additional post hoc analyses compared the reasons for missing data.2
CAMZYOS demonstrated significant improvements vs placebo in
patient-reported frequency and severity of shortness of breath as early as Week 4, with this improvement remaining consistent up to Week 301
See the safety profile
Please refer to the CAMZYOS Summary of Product Characteristics for further information on dosing, initiation and safety.
CI, confidence interval; HCMSQ-SoB, Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness-of-Breath; KCCQ-23 CSS, Kansas City Cardiomyopathy Questionnaire-23 Clinical Summary Score; LS, least square; LVOT, left ventricular outflow tract; NYHA, New York Heart Association; pVO2, peak oxygen consumption; SD, standard deviation; SoC, standard of care.
